Supplements · Exercise

Semaglutide 2.4 mg reduces the incidence of obesity-related complications and is cost-effective in Japan under retreatment scenarios.

In a lifetime economic model from a Japanese public payer perspective, semaglutide 2.4 mg plus diet and exercise reduced the incidence of obesity-related complications such as type 2 diabetes, cardiovascular events, obstructive sleep apnea, and gout compared to diet and exercise alone. The incremental cost-effectiveness ratio was ¥5,300,580/QALY for patients without type 2 diabetes and ¥7,077,984/QALY for those with type 2 diabetes, with retreatment improving QALY gains.

2 min read•Updated Jul 8, 2026•0 RCTs•View structured evidence →
Evidence Score34/100
Human RCT☆☆☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.

Semaglutide 2.4 mg reduces the incidence of obesity-related complications and is cost-effective in Japan under retreatment scenarios. The current body of evidence comprises 1 study. EvidenceHub rates the overall confidence at 34/100 (low).

The Claim

Semaglutide 2.4 mg reduces the incidence of obesity-related complications and is cost-effective in Japan under retreatment scenarios.

This conclusion is most relevant to: People with obesity disease in Japan meeting Optimal Use Promotion Guidelines criteria: BMI ≥35 kg/m² with at least 1 obesity-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes), or BMI ≥27 kg/m² with at least 2 obesity-related health disorders..

What the Research Shows

The conclusion draws on 1 linked study. Highlights from the cited literature:

  • ▸Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios. (Journal of health economics and outcomes research, 2026) —

How It Works

The proposed biological pathway:

  • ▸Semaglutide 2.4 mg activates GLP-1 receptors, reducing appetite and promoting weight loss.
  • ▸Weight loss reduces risk factors such as hypertension, dyslipidemia, and insulin resistance.
  • ▸Reduced risk factors lower the incidence of obesity-related complications like type 2 diabetes and cardiovascular events.
  • ▸Result: Improved quality-adjusted life years and reduced healthcare costs over a lifetime.

Who Might Benefit

Evidence fit by population:

  • ▸People with obesity disease in Japan meeting Optimal Use Promotion Guidelines criteria: BMI ≥35 kg/m² with at least 1 obesity-related comorbidity (hypertension, dyslipidemia, or type 2 diabetes), or BMI ≥27 kg/m² with at least 2 obesity-related health disorders.

Limitations & Caveats

Important context when interpreting this evidence:

  • ▸Uncertainty remains around retreatment efficacy and long-term discontinuation rates.
  • ▸The model relies on assumptions from Japanese studies, which may have limited generalizability to other populations or settings.

Frequently Asked Questions

What is the cost-effectiveness threshold in Japan for semaglutide 2.4 mg?▼

The study reports ICERs of ¥5.3 million/QALY for patients without type 2 diabetes and ¥7.1 million/QALY for those with type 2 diabetes, which are generally considered cost-effective in Japan.

Does retreatment with semaglutide improve outcomes?▼

Yes, the study found that retreatment (up to 2 retreatments with a 1-year off-treatment period) significantly improved QALY gains compared to limited or no retreatment.

What are the eligibility criteria for semaglutide in Japan?▼

Patients must have a BMI ≥35 kg/m² with at least one obesity-related comorbidity, or a BMI ≥27 kg/m² with at least two obesity-related health disorders, as per the Optimal Use Promotion Guidelines.

How does semaglutide reduce obesity-related complications?▼

Semaglutide promotes weight loss, which in turn reduces risk factors like hypertension, dyslipidemia, and insulin resistance, leading to lower incidence of complications such as type 2 diabetes and cardiovascular events.

References

  1. 1.Kamada Y, Wada S, Matsuda H, Dai Y. “Cost-Effectiveness of Semaglutide 2.4 mg for Obesity Disease Management in Japan: A Lifetime Economic Modeling Study Incorporating Retreatment Scenarios..” Journal of health economics and outcomes research, 2026. PMID: 42394652 DOI: 10.36469/001c.162614
Disclaimer: This article is auto-generated from structured research data for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.